ARUP Institute for Clinical & Experimental Pathology®

Created in 1996, the ARUP Institute for Clinical and Experimental Pathology® seeks to expand the quantity, quality, and utility of laboratory medicine. Since its inception, the institute has developed approximately 620 tests that ARUP now performs in-house. Of these 620 tests, more than 400 were developed by institute scientists, while more than 200 others were improved and validated so that ARUP could perform them in-house rather than continue to refer them out. Moreover, ARUP research scientists have shared their knowledge, experience, and new developments with the scientific community by publishing more than 1,600 original peer-reviewed research publications in leading journals.

The institute’s mission is to be at the forefront of innovative research and development in clinical and experimental laboratory medicine and to continually contribute to the profession.

Research Focus

The institute's focus covers the spectrum of medical laboratory medicine:

Executive Directors

Julio Delgado, MD, MS
Co-Executive Director
(801) 583-2787

 

Sherrie L. Perkins, MD, PhD
Co-Executive Director
(801) 581-5854

Project Categories

The ARUP Institute for Clinical and Experimental Pathology® sponsors projects within four broad categories: creating new laboratory tests; improving current clinical laboratory tests; evaluating and critiquing tests, including alpha- and beta-site protocols; and conducting basic and clinical research projects. Research performed on human subjects is conducted under informed consent following the protocols approved by the University of Utah Institutional Review Board (IRB).


 

Recent Publications

Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, Perou CM, Bernard PS, Nielsen TO. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Mod Pathol 2014;26(11):1438–50.

Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood 2014;124(22):3260–73.

Ray JA, Kushnir MM, Palmer J, Seyed S, Rockwood AL, Meikle AW. Enhancement of specificity of aldosterone measurement in human serum and plasma using 2D-LC-MS/MS and comparison with commercial immunoassays. J Chromatogr B Analyt Technol Biomed Life Sci 2014;970:102–7.

Okal A, Matissek KJ, Matissek SJ, Price R, Salama ME, Janát-Amsbury MM, Lim CS. Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model. Gene Ther 2014;21(10):903–12.

Petrides AK, Moskowitz J, Johnson-Davis KL, Jannetto PJ, Langman LJ, Clarke W, Marzinke MA. The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum. Clin Biochem 2014;47(15):73–9.